Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss mutation burden—its role in response to treatment with PD-L1 immunotherapy and its impact on progression-free survival and overall survival, as well as the link between intrinsic expression subtypes and treatment outcome with atezolizumab (Abstract 104).

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Heather A. Wakelee, MD, on Bevacizumab for Early-Stage NSCLC

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Heather A. Wakelee, MD, of Stanford University, discuss findings on adjuvant chemotherapy with or without bevacizumab for early-stage non–small cell lung cancer, with outcomes based on chemotherapy subsets (Abstract 8507).

Palliative Care

Ronald C. Chen, MD, MPH, on End-of-Life Care: Impact of the Choosing Wisely Campaign

Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, discusses the substantial overuse of aggressive medical care for younger patients at the end of life, despite ASCO recommendations (Abstract LBA10033).

Prostate Cancer

A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (Abstract 5006).

Issues in Oncology

Patricia J. Goldsmith on Patient Access and Engagement: Results of the CancerCare Report

Patricia J. Goldsmith, Chief Executive Officer of CancerCare, which provides free, professional support services to anyone affected by cancer, discusses findings from six distinct surveys with input from more than 3,000 individuals at varying stages of their cancer experience.

May

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab

Vali A. Papadimitrakopoulou, MD, and Heather A. Wakelee, MD, on Bevacizumab for Early-Stage NSCLC

Ronald C. Chen, MD, MPH, on End-of-Life Care: Impact of the Choosing Wisely Campaign

A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

Patricia J. Goldsmith on Patient Access and Engagement: Results of the CancerCare Report

Breast Density Reduction: Endoxifen vs Tamoxifen

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Advanced CKM Syndrome Associated With Greater Cancer Risk

Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL